Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

Authors:
  • PSPhilippe E. Spiess
    Philippe E. Spiess
  • NANeeraj Agarwal
    Neeraj Agarwal
  • RBRick Bangs
    Rick Bangs
  • SBStephen A. Boorjian
    Stephen A. Boorjian
  • MBMark K. Buyyounouski
    Mark K. Buyyounouski
  • PCPeter E. Clark
    Peter E. Clark
  • TDTracy M. Downs
    Tracy M. Downs
  • JEJason A. Efstathiou
    Jason A. Efstathiou
  • TFThomas W. Flaig
    Thomas W. Flaig
  • TFTerence Friedlander
    Terence Friedlander
  • RGRichard E. Greenberg
    Richard E. Greenberg
  • KGKhurshid A. Guru
    Khurshid A. Guru

Abstract
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on systemic therapy for muscle-invasive urothelial bladder cancer, as substantial revisions were made in the 2017 updates, such as new recommendations for nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab. The complete version of the NCCN Guidelines for Bladder Cancer addresses additional aspects of the management of bladder cancer, including non–muscle-invasive urothelial bladder cancer and nonurothelial histologies, as well as staging, evaluation, and follow-up.

This publication has 68 references indexed in Scilit: